EBV infection cannot be directly studied in mice because the virus is endemic to humans. In an attempt to overcome this problem, we and others have expressed LMP1 or LMP2A in mouse B cells (3, 4, 6, (20) (21) (22) (23) (Fig. 1C) . Activation of T and NK cells was also observed in mice co-expressing LMP1 and LMP2A in B cells (Fig. 1D ), but these animals exhibited a large expansion of LMP1/2A-expressing B cells concomitant with reduced T and NK cell expansion, and eventually succumbed to organ failure ( Fig. 1 A and C) .
Rag2 -/-γC -/-recipient mice reconstituted with bone marrow hematopoietic stem cells (HSCs) from 3 day old CD19-Cre; LMP1/LMP2A flSTOP mice died at 23-32 days after HSCs transplantation (Fig. S1B) . Those terminally ill mice had severe hyperplasia of LMP1 + LMP2A + B cells in bone marrow and spleen, even though T and NK cells were activated ( Fig. S1C and D) . Death of recipients was not observed when CD19-Cre; LMP1 flSTOP or CD19-Cre; LMP2A flSTOP HSCs were used for reconstitution (Fig. S1B ). These data indicate that combined expression of LMP1 and LMP2A in B cells early in life is lethal.
Expression of LMP1 and LMP2A in a small number of mature B cells as a model for acute EBV infection.
In order to model EBV infection more faithfully by restricting it to just a few initially infected naïve B cells, we crossed LMP1 flSTOP and LMP2A flSTOP animals with CD19-Cre ERT2 animals (22). Tamoxifen treatment of these mice led to expression of LMP1 and LMP2A in a small population of splenic B cells (~ 2 -5 %), as seen in reporter control animals crossed to CD19-Cre ERT2 (Fig. 2A) .
While the number of reporter+ B cells in these latter animals was stable over time, expression of LMP1, alone or together with LMP2A, led to strong cellular expansion of B cells, reaching its maximum on day 6 to 7 after tamoxifen treatment (Fig. 2B) . The surface phenotype of these cells (CD19 + CD38 high IgD high ) suggests that they originate from naïve follicular B cells (Fig. S2A ). This was followed by a strong expansion of T cells, mainly of the CD8 subset, accompanied by a dramatic reduction of reporter + B cells. The strong lymphoproliferation led to splenomegaly and liver infiltration of T and B cells between day 5 and 8.
However, reporter + B cells were no longer observed from day 10 on (Fig. 2B and C).
The expanding T cells developed the phenotype of effector/memory T cells at around day 6 after tamoxifen treatment, as seen by loss of CD62L and gain of CD44 and PD-1 (Fig. 2D, Fig. S2B ). Both CD4 and CD8 T cells showed classical pro-inflammatory TNFα and IFNγ expression (Fig. S2C) . At later timepoints, more than half of the CD8 T cells of CD19-Cre ERT2 ; LMP1/LMP2A flSTOP mice were still high in CD44 surface expression, an established marker for memory T cells (Fig. 2D) , suggesting the formation of immunological memory. (Fig. 3A) . Similarly, LMP1 flSTOP B cells, in which expression of LMP1 was induced in vitro by TAT-Cre treatment, were killed by activated T cells from these mice, but not LMP1 flSTOP B cells activated by anti-CD40 stimulation (Fig. S2D) . None of these targets were killed by T cells isolated from CD19-Cre ERT2 ; hCD2 flSTOP mice 8 days after tamoxifen treatment.
These results indicate that the activated CD8 T cells kill LMP-driven B cell blasts in an antigen-specific, MHC-restricted manner, in line with our earlier data on T cell surveillance of LMP1-induced B cell lymphomas in the mouse (21) and data from the human (25).
To test whether the T cells are indeed controlling LMP1/LMP2A expressing B cell outgrowth in our IM model, we performed antibody-mediated T cell depletion in CD19-Cre ERT2 ; LMP1/LMP2A flSTOP animals shortly before tamoxifen treatment. Animals that were not T cell-depleted showed large numbers of T cells, while reporter + B cells were absent on day 9 after tamoxifen treatment.
Conversely, animals that were treated with T cell depleting antibodies showed strong expansion of reporter + B cells in the spleen (Fig. 3B ). Of note, in the course of this experiment some T cell-depleted animals reached termination criteria, likely due to overwhelming expansion of reporter + B cells.
Modeling fatal EBV infection.
While the healthy human immune system is able to control EBV-infection, a number of primary immunodeficiencies predispose patients to fatal EBVassociated hematological diseases (5, 6) . Among those are inactivating mutations of perforin, a protein that is required for Granzyme-mediated T cell killing.
Because we observed that direct CD8 T cell-mediated killing is involved in the control of LMP1/LMP2A-expressing B cells in our mouse model, we crossed CD19-Cre ERT2 ; LMP1 flSTOP and CD19-Cre ERT2 ; LMP1/LMP2A flSTOP animals with perforin-deficient animals. When these mice were treated with tamoxifen, more than 75 % of animals reached termination criteria on day 6 after tamoxifen treatment (Fig. 3 C) , with pronounced spleen and liver infiltration with reporter + B cells compared to perforin-sufficient animals (Fig. S2E ). Strong activation of T cells could be observed in both perforin-sufficient and -deficient animals ( Fig.   S2F ). Thus, the present mouse model of acute EBV infection opens the way to a functional analysis of at least one of the EBV-related human immunodeficiencies.
Expression of LMP1 and LMP2A in GC B cells leads to fatal B cell expansion upon immunosuppressive treatment.
We then studied the function of LMP1 and LMP2A in GC B cells, as these proteins are frequently co-expressed in GC-derived EBV + lymphomas. We used Cγ1-Cre, which is active in GC B cells (26), to drive expression of LMP1 and LMP2A, either alone or in combination. 10 days after immunization with the hapten 4-hydroxy-3-nitro-phenylacetyl coupled to chicken gamma globulin (NP-CGG) we analyzed the frequencies of GC B cells (CD19 + Fas high CD38 low ) in the spleen (Fig. 4A ).
Control mice expressing only the reporter showed a clear GC population, while in Cγ1-Cre; LMP1 flSTOP mice the frequency of GC B cells was markedly reduced. This reduction was even more pronounced when LMP2A was co-expressed. The total number of reporter + cells was similarly reduced (Fig. 4C) . Expression of LMP2A alone had no significant effect (Fig. 4 B and C) .
Interestingly, the few reporter + cells found in Cγ1-Cre; LMP1 flSTOP mice were able to proliferate when they were isolated and cultured in vitro and this proliferation was stronger when LMP2A was co-expressed ( Fig. S3A and B) . To test whether LMP expressing GC B cells are under T cell immunosurveillance, we treated mice expressing LMP1 and/or LMP2A in GC B cells with a T cell-depleting antibody cocktail starting on day 10 after immunization. This led to massive expansion of GC B cells co-expressing LMP1 and LMP2A, but not of GC B cells expressing LMP1 or LMP2A alone (Fig. 4 B and C) . This expansion was ultimately fatal (Fig. 4D) and was associated with enlarged spleens (Fig. S3C) , where GCs were histologically undetectable (Fig. S3D) . Analysis of IgH VH gene usage showed that the expanding B cell population was polyclonal in nature ( Apparently, LMP1 plays a critical role in this process.
The present study was designed to determine the effects of combined LMP2A and LMP1 expression in mouse B cells and to better mimic viral infection by timed and restricted expression of the LMPs. LMP1/LMP2A co-expression under the control of CD19-Cre in early B cells was lethal, as opposed to LMP1 or LMP2A single-expression (Fig. 1) . We therefore induced expression of LMP1 and LMP2A using the CD19-Cre ERT2 allele and tamoxifen such that expression occurred in only a small fraction of naïve B cells in adult mice. This system faithfully recapitulated the initial expansion of EBV-infected (LMP1 and LMP2A coexpressing) B cell blasts in human IM, the subsequent activation and expansion of T cells and the clearance of the B cell blasts (Fig. 2) . Immunosuppressive treatment by T cell depletion led to uncontrolled expansion of B cells coexpressing LMP1 and LMP2A (Fig. 3) . We also showed that this system can be used to model at least one form of FHL, by crossing the mice to a Prf1-deficient background. While Prf1-proficient T cells were able to control LMP1-and LMP2A-expressing B cell blasts, Prf1-deficient T cells failed to do so (Fig. 3) . Notably, however, this was not the case for LMP1 or LMP2A single-expressing GC cells (Fig. 4) . LMP2A might therefore play a role in GC B cell transformation that goes beyond the well-described rescue of GC B cells that have acquired "crippling" somatic mutations (9) (Fig. 4) . By replacing LMP2A with an active form of PI3K, we showed that activation of PI3K is likely the major mechanism by which LMP2A co-expression with LMP1 causes a phenotype that so dramatically differs from LMP1 single-expression (Fig. 4) . 
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